Kaat Ramaekers

Kaat Ramaekers

Auto-generated profile, based on publicly available information

Kaat Ramaekers

KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Clinical and Epidemiological Virology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in The Lancet Global Health
Verified
Journal Article
Open access
YLYou Li
You Li
RRRachel M Reeves
Rachel M Reeves
XWXin Wang
Xin Wang
QBQuique Bassat
Quique Bassat
WBW Abdullah Brooks
W Abdullah Brooks
HZHeather J Zar
Heather J Zar
Influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus are the most common viruses associated with acute lower respiratory infections in young children (<5 years) and older people (≥65 years). A global report of the monthly activity of these viruses is needed to inform public health strategies and programmes for their control. In this systematic analysis, we compiled data from a systematic literature review of studies published between Jan 1, 2000, and Dec 31, 2017; online datasets; and unpublished research data. Studies were eligible for inclusion if they reported laboratory-confirmed incidence data of human infection of influenza virus, respiratory syncytial virus, parainfluenza virus, or metapneumovirus, or a combination of these, for at least 12 consecutive months (or 52 weeks equivalent); stable testing practice throughout all years reported; virus results among residents in well-defined geographical locations; and aggregated virus results at least on a monthly basis. Data were extracted through a three-stage process, from which we calculated monthly annual average percentage (AAP) as the relative strength of virus activity. We defined duration of epidemics as the minimum number of months to account for 75% of annual positive samples, with each component month defined as an epidemic month. Furthermore, we modelled monthly AAP of influenza virus and respiratory syncytial virus using site-specific temperature and relative humidity for the prediction of local average epidemic months. We also predicted global epidemic months of influenza virus and respiratory syncytial virus on a 5° by 5° grid. The systematic review in this study is registered with PROSPERO, number CRD42018091628. We initally identified 37 335 eligible studies. Of 21 065 studies remaining after exclusion of duplicates, 1081 full-text articles were assessed for eligibility, of which 185 were identified as eligible. We included 246 sites for influenza virus, 183 sites for respiratory syncytial virus, 83 sites for parainfluenza virus, and 65 sites for metapneumovirus. Influenza virus had clear seasonal epidemics in winter months in most temperate sites but timing of epidemics was more variable and less seasonal with decreasing distance from the equator. Unlike influenza virus, respiratory syncytial virus had clear seasonal epidemics in both temperate and tropical regions, starting in late summer months in the tropics of each hemisphere, reaching most temperate sites in winter months. In most temperate sites, influenza virus epidemics occurred later than respiratory syncytial virus (by 0·3 months [95% CI -0·3 to 0·9]) while no clear temporal order was observed in the tropics. Parainfluenza virus epidemics were found mostly in spring and early summer months in each hemisphere. Metapneumovirus epidemics occurred in late winter and spring in most temperate sites but the timing of epidemics was more diverse in the tropics. Influenza virus epidemics had shorter duration (3·8 months [3·6 to 4·0]) in temperate sites and longer duration (5·2 months [4·9 to 5·5]) in the tropics. Duration of epidemics was similar across all sites for respiratory syncytial virus (4·6 months [4·3 to 4·8]), as it was for metapneumovirus (4·8 months [4·4 to 5·1]). By comparison, parainfluenza virus had longer duration of epidemics (6·3 months [6·0 to 6·7]). Our model had good predictability in the average epidemic months of influenza virus in temperate regions and respiratory syncytial virus in both temperate and tropical regions. Through leave-one-out cross validation, the overall prediction error in the onset of epidemics was within 1 month (influenza virus -0·2 months [-0·6 to 0·1]; respiratory syncytial virus 0·1 months [-0·2 to 0·4]). This study is the first to provide global representations of month-by-month activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus. Our model is helpful in predicting the local onset month of influenza virus and respiratory syncytial virus epidemics. The seasonality information has important implications for health services planning, the timing of respiratory syncytial virus passive prophylaxis, and the strategy of influenza virus and future respiratory syncytial virus vaccination. European Union Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).

1 July 2020 in Virus Evolution
Verified
Journal Article
Open access
KRKaat Ramaekers
Kaat Ramaekers
ARAnnabel Rector
Annabel Rector
LCLize Cuypers
Lize Cuypers
PLPhilippe Lemey
Philippe Lemey
EKEls Keyaerts
Els Keyaerts
MRMarc Van Ranst
Marc Van Ranst
Since the first human respiratory syncytial virus (HRSV) genotype classification in 1998, inconsistent conclusions have been drawn regarding the criteria that define HRSV genotypes and their nomenclature, challenging data comparisons between research groups. In this study, we aim to unify the field of HRSV genotype classification by reviewing the different methods that have been used in the past to define HRSV genotypes and by proposing a new classification procedure, based on well-established phylogenetic methods. All available complete HRSV genomes (>12,000 bp) were downloaded from GenBank and divided into the two subgroups: HRSV-A and HRSV-B. From whole-genome alignments, the regions that correspond to the open reading frame of the glycoprotein G and the second hypervariable region (HVR2) of the ectodomain were extracted. In the resulting partial alignments, the phylogenetic signal within each fragment was assessed. Maximum likelihood phylogenetic trees were reconstructed using the complete genome alignments. Patristic distances were calculated between all pairs of tips in the phylogenetic tree and summarized as a density plot in order to determine a cutoff value at the lowest point following the major distance peak. Our data show that neither the HVR2 fragment nor the G gene contains sufficient phylogenetic signal to perform reliable phylogenetic reconstruction. Therefore, whole-genome alignments were used to determine HRSV genotypes. We define a genotype using the following criteria: a bootstrap support of ≥70 per cent for the respective clade and a maximum patristic distance between all members of the clade of ≤0.018 substitutions per site for HRSV-A or ≤0.026 substitutions per site for HRSV-B. By applying this definition, we distinguish twenty-three genotypes within subtype HRSV-A and six genotypes within subtype HRSV-B. Applying the genotype criteria on subsampled data sets confirmed the robustness of the method.

1 September 2017 in Journal of Clinical Virology
Verified
Journal Article
Closed access
KRKaat Ramaekers
Kaat Ramaekers
EKEls Keyaerts
Els Keyaerts
ARAnnabel Rector
Annabel Rector
ABAnnie Borremans
Annie Borremans
KBKurt Beuselinck
Kurt Beuselinck
MRMarc Van Ranst
Marc Van Ranst

1 January 2016 in Disease Models & Mechanisms
Verified
Journal Article
Open access
PDF file
YDYannick Debing
Yannick Debing
NMNiraj Mishra
Niraj Mishra
EVErik Verbeken
Erik Verbeken
KRKaat Ramaekers
Kaat Ramaekers
KDKai Dallmeier
Kai Dallmeier
JNJohan Hendrik Neyts
Johan Hendrik Neyts
Hepatitis E virus (HEV) is one of the prime causes of acute viral hepatitis, whereas chronic hepatitis E is increasingly recognized as an important problem in the transplant setting. Nevertheless, the fundamental understanding of the biology of HEV replication is limited and there are few therapeutic options. The development of such therapies is partially hindered by the lack of a robust and convenient animal model. We propose the infection of athymic nude rats with the rat HEV strain LA-B350 as such a model. A cDNA clone pLA-B350 was constructed and the infectivity of its capped RNA transcripts was confirmed in vitro and in vivo. Furthermore, a subgenomic replicon pLA-B350/luc was constructed and validated for in vitro antiviral studies. Interestingly, rat HEV proved to be less sensitive to the antiviral activity of alpha interferon, ribavirin and mycophenolic acid, than genotype 3 HEV. As a proof-of-concept, part of the C-terminal polymerase sequence of pLA-B350/luc was swapped with its genotype 3 HEV counterpart: the resulting chimeric replicon replicated with comparable efficiency as the wild-type construct, confirming that LA-B350 is amenable to humanization. Finally, ribavirin effectively inhibited LA-B350 replication in athymic nude rats, confirming the suitability of the rat model for antiviral studies.

14 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SGStephanie Goya
Stephanie Goya
CRChristopher Ruis
Christopher Ruis
RNRichard A. Neher
Richard A. Neher
AMAdam Meijer
Adam Meijer
AAAmmar Aziz
Ammar Aziz
MVMARIANA VIEGAS
MARIANA VIEGAS
A globally implemented unified classification for human respiratory syncytial virus (HRSV) below the subgroup level remains elusive. Here, we formulate the global consensus of HRSV classification based on the challenges and limitations of our previous proposals and the future of genomic surveillance. From a high-quality dataset of 1,480 HRSV-A and 1,385 HRSV-B genomes submitted to NCBI and GISAID up to March 2023, we categorized HRSV-A/B sequences into lineages based on phylogenetic clades and amino acid markers. We defined 24 lineages within HRSV-A and 16 within HRSV-B, providing guidelines for prospective lineages definition. Our classification demonstrated robustness in its applicability to both complete and partial genomes. In addition, it allowed the observation of notable lineage replacements and the identification of lineages exclusively detected since the COVID-19 pandemic. We envision that this unified HRSV classification proposal will strengthen and facilitate HRSV molecular epidemiology on a global scale.

26 December 2019 in Transdisciplinary Insights
Verified
Journal Article
Closed access
ECEllie Cassandra Clark
Ellie Cassandra Clark
FRFlorian De Rop
Florian De Rop
IGIria Anne Jimenez Garcia
Iria Anne Jimenez Garcia
ANAna Nogal
Ana Nogal
RMRuel Alexander Mannette
Ruel Alexander Mannette
CVCorinne Vandermeulen
Corinne Vandermeulen
This abstract is a report of the investigations by a transdisciplinary team working on the ‘Vaccine Confidence’ challenge (Supplement 1). Since their introduction, vaccines have been one of the most successful health interventions in medicine. Prior to vaccination programs against poliomyelitis, more than 350,000 cases of polio were reported annually worldwide, a number that decreased to just 33 reported cases in 20181. Additionally, between 2000 and 2017, the measles vaccination program is estimated to have prevented 21.1 million deaths.2 However, in 2018 more than 19 million children under one year of age did not receive the recommended WHO vaccines.3 A recent rise in anti-vaccine or vaccination-hesitant mentalities has led to decreasing vaccine coverage in several Western countries. The WHO identified three C’s as main determinants of vaccine hesitancy, namely Complacency, Convenience in accessing vaccines, and Confidence. However, the term ‘vaccine hesitancy’ tends to be interpreted as a lack of confidence in vaccines and vaccinations for various reasons. Nevertheless, the goal of vaccination is to reach herd immunity by reaching a high vaccination coverage (90‐95% vaccinated) to stop the circulation of vaccine preventable diseases. We wanted to give equal attention to the three C’s as they are equally important in reaching herd immunity. Therefore, we chose to present the problem as a challenge of ‘vaccine coverage,’ rather than ‘vaccine hesitancy’ or ‘vaccine confidence’. In order to understand the complexity of the problem, we have developed a systems map which relates different global factors that impact an individual’s vaccination decision-making, as well as their likelihood of receiving vaccinations (Supplement 2). To create this map we assembled the information for the variables and connections from literature studies of peer-reviewed articles and interviews with stakeholders, kept anonymous, in the field of vaccination or healthcare (Supplements 3 & 4). This approach was selected as it provides a wide perspective that allows academics, governmental authorities, and lawmakers to better assess the various factors that affect vaccine coverage, and how they are related. The work leading to the map was presented to the public at a symposium (Supplement 5). Our map identifies essential factors such as psychology, education, economy, vaccine technology, political and environmental sphere, sources of information, and healthcare in order to understand what governs vaccination coverage. The map emphasizes how various factors and determinants are often interrelated, as opposed to the isolated factors described in previous literature. We identified important discrepancies between developed and developing countries regarding the factors that drive vaccine-related decision-making and availability. The systems map could ultimately serve as a tool to better understand the multifaceted problem of suboptimal vaccination coverage. Vaccine hesitancy as a threat to vaccination coverage is a complex and wicked problem with many underlying contributing factors, as has been depicted in our systems map on vaccine coverage. Our systems map allows more in-depth insights, not only into which factors are contributing, but also into the relationship between factors. Solving the decrease in vaccination coverage will require different types of solutions which can be developed by using a transdisciplinary approach.